Clinical Significance Fit (nejm-fit)
Why this is skill #1
NEJM triages the large majority of submissions to rejection without external review. The gate is not "is the study sound" — it is "would this change clinical practice, and is the evidence definitive enough to justify that change." A well-conducted but narrow study is desk-rejected. Run this before investing in prose.
When to trigger
- Before drafting, to decide if NEJM is even the right venue.
- When a co-author says "this is an NEJM paper" and you need a sober second opinion.
- When choosing between NEJM, Lancet, JAMA, a specialty journal (e.g., Circulation, Blood, JCO), and NEJM Evidence.
The three gates (all must hold)
NEJM weighs three things together. A paper passes only if it clears all three:
- Clinical importance — does it address a question clinicians and patients actually face, with an outcome that matters (mortality, major morbidity, function, quality of life — not just a surrogate)?
- Methodological rigor — is the design strong enough that the result is believable and not likely to be overturned (adequately powered RCT, rigorous observational design with confounding addressed)?
- Generalizability — do the findings extend beyond a single center / narrow population to the broad practice community NEJM serves?
A large RCT with a surrogate endpoint can still fail gate 1. A striking finding from one underpowered single-center study fails gates 2–3.
Significance ladder (weak → strong)
- Case report / small case series. (Weak — correspondence or specialty journal.)
- Mechanistic or early-phase finding without clinical outcomes. (Specialty / translational journal.)
- Single rigorous study extending known effects to a new population. (Borderline — JAMA/Lancet/specialty.)
- Definitive RCT or landmark study answering a practice question with a hard outcome. (Strong.)
- Practice-changing trial that resolves a controversy or sets a new standard of care. (Strongest.)
If you cannot place the work at rung 4+, NEJM is a long shot — be honest with the user and name the realistic target.
Fatal desk-reject triggers
- Outcome is a surrogate (lab value, imaging marker) with no patient-important endpoint.
- Underpowered for the primary outcome, or the primary outcome was changed post hoc.
- Single-center, narrow population, with no claim to generalizability.
- Not prospectively registered for a trial (an ICMJE deal-breaker — see
nejm-study-design).
- Over-claiming: causal language on observational data, or a subgroup result sold as the main finding.
- Incremental over the authors' own prior trial with no new practice implication.
Venue routing
| Situation |
Recommend |
| Definitive, practice-changing, generalizable RCT/landmark study |
NEJM (Original Article) |
| Rigorous and important, but global-health or broad public-health framing |
The Lancet |
| Strong clinical trial/study, large general-medicine audience |
JAMA |
| Methodologically strong, fits open-science/registration ethos |
BMJ |
| Important to one specialty, not broad practice |
specialty journal (Circulation, Blood, JCO, …) |
| Solid but not top-tier general impact; pragmatic/methods focus |
NEJM Evidence / specialty |
| Early-phase / mechanism / surrogate only |
translational or specialty journal |
Output format
【Three gates】 clinical importance / rigor / generalizability — pass or fail each, one line
【Significance rung】 1–5 + one-line justification
【Outcome type】 patient-important / surrogate-only → flag if surrogate
【Fatal triggers present】 [...]
【Recommended venue】 NEJM / Lancet / JAMA / BMJ / specialty / NEJM Evidence
【If staying with NEJM, the single sentence of practice-changing impact】 "..."
【Next】 nejm-study-design (if pass) | reconsider venue (if fail)
Anti-patterns
- Do not rationalize a narrow result into "practice-changing" with adjectives — editors discount adjectives.
- Do not confuse a statistically significant surrogate endpoint with clinical importance.
- Do not let sample size alone stand in for rigor — a large biased study is still biased.
- Do not let sunk cost ("the trial took five years") drive the venue decision.
Source: brycewang-stanford/Awesome-Journal-Skills → NEJM-Skills/skills/nejm-fit/SKILL.md
1---2name: nejm-fit3description: Use this first, before any writing, to stress-test whether a clinical study clears NEJM's bar — practice-changing clinical impact, methodological rigor, and generalizability. Decides NEJM vs Lancet/JAMA vs a specialty journal.4---5
6
7# Clinical Significance Fit (nejm-fit)
8
9## Why this is skill #1
10
11NEJM triages **the large majority of submissions to rejection without external review**. The gate is not "is the study sound" — it is **"would this change clinical practice, and is the evidence definitive enough to justify that change."** A well-conducted but narrow study is desk-rejected. Run this before investing in prose.
12
13## When to trigger
14
15- Before drafting, to decide if NEJM is even the right venue.
16- When a co-author says "this is an NEJM paper" and you need a sober second opinion.
17- When choosing between NEJM, Lancet, JAMA, a specialty journal (e.g., Circulation, Blood, JCO), and NEJM Evidence.
18
19## The three gates (all must hold)
20
21NEJM weighs three things together. A paper passes only if it clears all three:
22
231. **Clinical importance** — does it address a question clinicians and patients actually face, with an outcome that matters (mortality, major morbidity, function, quality of life — not just a surrogate)?
242. **Methodological rigor** — is the design strong enough that the result is believable and not likely to be overturned (adequately powered RCT, rigorous observational design with confounding addressed)?
253. **Generalizability** — do the findings extend beyond a single center / narrow population to the broad practice community NEJM serves?
26
27A large RCT with a surrogate endpoint can still fail gate 1. A striking finding from one underpowered single-center study fails gates 2–3.
28
29## Significance ladder (weak → strong)
30
311. **Case report / small case series.** (Weak — correspondence or specialty journal.)
322. **Mechanistic or early-phase finding** without clinical outcomes. (Specialty / translational journal.)
333. **Single rigorous study extending known effects** to a new population. (Borderline — JAMA/Lancet/specialty.)
344. **Definitive RCT or landmark study answering a practice question** with a hard outcome. (Strong.)
355. **Practice-changing trial that resolves a controversy or sets a new standard of care.** (Strongest.)
36
37If you cannot place the work at rung 4+, NEJM is a long shot — be honest with the user and name the realistic target.
38
39## Fatal desk-reject triggers
40
41- Outcome is a **surrogate** (lab value, imaging marker) with no patient-important endpoint.
42- **Underpowered** for the primary outcome, or the primary outcome was changed post hoc.
43- **Single-center**, narrow population, with no claim to generalizability.
44- **Not prospectively registered** for a trial (an ICMJE deal-breaker — see `nejm-study-design`).
45- **Over-claiming**: causal language on observational data, or a subgroup result sold as the main finding.
46- Incremental over the authors' own prior trial with no new practice implication.
47
48## Venue routing
49
50| Situation | Recommend |
51|--------------------------------------------------------------------|------------------------------------|
52| Definitive, practice-changing, generalizable RCT/landmark study | **NEJM** (Original Article) |
53| Rigorous and important, but global-health or broad public-health framing | **The Lancet** |
54| Strong clinical trial/study, large general-medicine audience | **JAMA** |
55| Methodologically strong, fits open-science/registration ethos | **BMJ** |
56| Important to one specialty, not broad practice | **specialty journal** (Circulation, Blood, JCO, …) |
57| Solid but not top-tier general impact; pragmatic/methods focus | **NEJM Evidence** / specialty |
58| Early-phase / mechanism / surrogate only | translational or specialty journal |
59
60## Output format
61
62```
63【Three gates】 clinical importance / rigor / generalizability — pass or fail each, one line
64【Significance rung】 1–5 + one-line justification
65【Outcome type】 patient-important / surrogate-only → flag if surrogate
66【Fatal triggers present】 [...]
67【Recommended venue】 NEJM / Lancet / JAMA / BMJ / specialty / NEJM Evidence
68【If staying with NEJM, the single sentence of practice-changing impact】 "..."
69【Next】 nejm-study-design (if pass) | reconsider venue (if fail)
70```
71
72## Anti-patterns
73
74- **Do not** rationalize a narrow result into "practice-changing" with adjectives — editors discount adjectives.
75- **Do not** confuse a statistically significant surrogate endpoint with clinical importance.
76- **Do not** let sample size alone stand in for rigor — a large biased study is still biased.
77- **Do not** let sunk cost ("the trial took five years") drive the venue decision.
78
79---
80
81**Source:** [`brycewang-stanford/Awesome-Journal-Skills`](https://github.com/brycewang-stanford/Awesome-Journal-Skills) → `NEJM-Skills/skills/nejm-fit/SKILL.md`
thedixitjain